SG11201803976VA - Polypeptides inhibiting cd40l - Google Patents

Polypeptides inhibiting cd40l

Info

Publication number
SG11201803976VA
SG11201803976VA SG11201803976VA SG11201803976VA SG11201803976VA SG 11201803976V A SG11201803976V A SG 11201803976VA SG 11201803976V A SG11201803976V A SG 11201803976VA SG 11201803976V A SG11201803976V A SG 11201803976VA SG 11201803976V A SG11201803976V A SG 11201803976VA
Authority
SG
Singapore
Prior art keywords
international
polypeptides
cd4ol
pct
publication
Prior art date
Application number
SG11201803976VA
Other languages
English (en)
Inventor
Els Pattyn
Ariella Van De Sompel
Peter Meerts
Marie-Ange Buyse
Maarten Dewilde
Gerald Beste
Jaromir Vlach
Jonathan Hsu
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of SG11201803976VA publication Critical patent/SG11201803976VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
SG11201803976VA 2015-11-27 2016-11-28 Polypeptides inhibiting cd40l SG11201803976VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260411P 2015-11-27 2015-11-27
US201662345967P 2016-06-06 2016-06-06
PCT/EP2016/079048 WO2017089618A1 (en) 2015-11-27 2016-11-28 Polypeptides inhibiting cd40l

Publications (1)

Publication Number Publication Date
SG11201803976VA true SG11201803976VA (en) 2018-06-28

Family

ID=57471837

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913503VA SG10201913503VA (en) 2015-11-27 2016-11-28 Polypeptides inhibiting cd40l
SG11201803976VA SG11201803976VA (en) 2015-11-27 2016-11-28 Polypeptides inhibiting cd40l

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913503VA SG10201913503VA (en) 2015-11-27 2016-11-28 Polypeptides inhibiting cd40l

Country Status (22)

Country Link
US (1) US11248055B2 (de)
EP (2) EP3932945A1 (de)
JP (1) JP7256011B2 (de)
KR (1) KR20180080337A (de)
CN (1) CN108473561B (de)
AU (1) AU2016360987A1 (de)
BR (1) BR112018010802A2 (de)
CA (1) CA3006398A1 (de)
CL (1) CL2018001400A1 (de)
CO (1) CO2018005921A2 (de)
DO (1) DOP2018000128A (de)
EC (1) ECSP18046820A (de)
GT (1) GT201800102A (de)
IL (1) IL259249A (de)
MA (1) MA43302A (de)
MX (1) MX2018006377A (de)
PE (1) PE20181956A1 (de)
PH (1) PH12018501114A1 (de)
RU (1) RU2018122255A (de)
SG (2) SG10201913503VA (de)
TN (1) TN2018000180A1 (de)
WO (1) WO2017089618A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Immunoglobulin sites with a single variable enhance serum albumin binding
CA3050575A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
SG11201906341XA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
US11673954B2 (en) * 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ATE452207T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (de) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
WO1997049805A2 (en) 1996-06-27 1997-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
EP0967284A1 (de) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterasen
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
CN100434441C (zh) 1999-04-22 2008-11-19 荷兰联合利华有限公司 利用单价抗原-结合蛋白抑制病毒感染
JP2003508031A (ja) 1999-06-18 2003-03-04 スィーヴィー セラピューティクス インコーポレイテッド Ａｔｐ結合カセット輸送体蛋白質ａｂｃ１を用いるコレステロール流出を増加させｈｄｌを上昇させるための組成物および方法
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
DK1242460T3 (da) 1999-11-29 2006-12-11 Unilever Nv Immobilisering af proteiner ved hjælp af et polypeptidsegment
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
EP1134231B1 (de) 2000-03-14 2009-04-15 Unilever N.V. Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
DK1360207T3 (da) 2000-12-13 2011-09-05 Bac Ip B V Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler
EP1377306A1 (de) 2001-03-09 2004-01-07 Dyax Corp. Serumalbumin-bindende anteile
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (de) 2001-12-11 2004-09-15 AlgoNomics N.V. Vefahren für die ausstellung von loops aus immunogloblin-domänen
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
WO2004037999A2 (en) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP3299393A1 (de) 2002-11-08 2018-03-28 Ablynx N.V. Gegen den tumornekrosefaktor-alpha gerichtete antikörper mit einfacher domäne und verwendungen dafür
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
DK1888640T3 (da) * 2005-05-18 2012-06-18 Ablynx Nv Forbedrede nanobodies mod tumornekrosefaktor-alfa
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2008101985A2 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CN101679521B (zh) 2007-03-22 2014-03-12 拜奥根Idec马萨诸塞公司 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
BRPI0812298A2 (pt) 2007-05-24 2016-05-24 Ablynx Nv sequência de aminoácidos direcionada contra rankl e polipeptídeos compreendendo a mesma para o tratamento de transtornos e doenças ósseas.
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
JP5723769B2 (ja) * 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US8962807B2 (en) * 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2012175400A1 (en) * 2011-06-23 2012-12-27 Ablynx Nv Serum albumin binding proteins
WO2012175741A2 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33827A (es) * 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
KR101637915B1 (ko) * 2011-10-13 2016-07-11 브리스톨-마이어스 스큅 컴퍼니 Cd40l을 길항하는 항체 폴리펩티드
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
US20170051059A1 (en) * 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
EP3331548A4 (de) 2015-07-14 2019-02-13 Immunext, Inc. Anti-cd154-antikörper mit verbesserter bindung, funktions- und sicherheitsmerkmalen und verwendung in der menschlichen immuntherapie
EP3331563B1 (de) 2015-08-05 2023-04-19 Janssen Biotech, Inc. Anti-cd154-antikörper und verfahren zur verwendung davon

Also Published As

Publication number Publication date
DOP2018000128A (es) 2018-09-30
EP3380517B1 (de) 2021-08-04
US20180355050A1 (en) 2018-12-13
JP7256011B2 (ja) 2023-04-11
TN2018000180A1 (en) 2019-10-04
SG10201913503VA (en) 2020-03-30
MX2018006377A (es) 2018-09-05
EP3932945A1 (de) 2022-01-05
CL2018001400A1 (es) 2018-10-26
US11248055B2 (en) 2022-02-15
BR112018010802A2 (pt) 2018-11-27
ECSP18046820A (es) 2018-07-31
CN108473561B (zh) 2022-12-16
CA3006398A1 (en) 2017-06-01
GT201800102A (es) 2019-08-15
CO2018005921A2 (es) 2018-06-20
KR20180080337A (ko) 2018-07-11
RU2018122255A3 (de) 2020-04-06
PH12018501114A1 (en) 2019-01-28
CN108473561A (zh) 2018-08-31
RU2018122255A (ru) 2019-12-19
WO2017089618A1 (en) 2017-06-01
IL259249A (en) 2018-07-31
MA43302A (fr) 2021-03-17
EP3380517A1 (de) 2018-10-03
JP2019504822A (ja) 2019-02-21
AU2016360987A1 (en) 2018-06-07
PE20181956A1 (es) 2018-12-17

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201803976VA (en) Polypeptides inhibiting cd40l
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201808751SA (en) T cell receptors
SG11201808750PA (en) T cell receptors
SG11201909918XA (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201908391XA (en) Methods for modulating an immune response
SG11201901141WA (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909914RA (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
SG11201805645QA (en) Lsd1 inhibitors
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201908680YA (en) Methods and compositions for preparing nucleic acid libraries
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts